MacroGenics (MGNX) Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MGNX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$5.10 |
| 52 Week Low | US$0.99 |
| Beta | 1.61 |
| 1 Month Change | -3.43% |
| 3 Month Change | 8.33% |
| 1 Year Change | -50.29% |
| 3 Year Change | -65.15% |
| 5 Year Change | -91.98% |
| Change since IPO | -93.24% |
Recent News & Updates
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Sep 08
MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets
Sep 05Recent updates
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Sep 08MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets
Sep 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Jul 24Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
May 21MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Apr 14
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Feb 28MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Feb 27MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Dec 05Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Shareholder Returns
| MGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.3% | 1.3% | 2.6% |
| 1Y | -50.3% | 3.4% | 19.0% |
Return vs Industry: MGNX underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: MGNX underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 341 | Eric Risser | www.macrogenics.com |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs.
MacroGenics, Inc. Fundamentals Summary
| MGNX fundamental statistics | |
|---|---|
| Market cap | US$116.93m |
| Earnings (TTM) | -US$36.40m |
| Revenue (TTM) | US$165.50m |
Is MGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNX income statement (TTM) | |
|---|---|
| Revenue | US$165.50m |
| Cost of Revenue | US$181.59m |
| Gross Profit | -US$16.09m |
| Other Expenses | US$20.31m |
| Earnings | -US$36.40m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | -9.72% |
| Net Profit Margin | -21.99% |
| Debt/Equity Ratio | 150.7% |
How did MGNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 15:14 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Stephen V. Byrne | BofA Global Research |